Company intelligence / Profile preview
J2H Biotech
Suwon-si, Gyeonggi-do, South Koreaj2hbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
J2H-1702 is currently in Phase 2 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a 25% phase transition success rate. J2H-1701 is in Phase 1 for Hepatitis C.
- Therapeutic areas
- PulmonologyMetabolic DisordersOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesProteolysis-targeting chimeras (PROTAC)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Institut Pasteur Korea (IPK)Shinhan Venture Investment
Beyond the preview
Go deeper on J2H Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on J2H Biotech.